Archive: February 03 2021

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Immunotherapy Web Featured Images 92

L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL

During a Targeted Oncology Case Based Peer Perspectives Roundtable event, Loretta J. Nastoupil, MD, discussed the case of a 74-year-old patients with diffuse large B-cell lymphoma.

Visit website
Immunotherapy Web Featured Images 93

CAR-T Meeting 2021 | Keynote lectures and BiTE vs CAR-T debate

  Feb 03 2021 Tagged CAR-T, BiTE

Nicolaus Kröger, MD, University Medical Center Hamburg, Hamburg, Germany, describes what he is looking forward to from the upcoming European CAR T-cell Meeting 2021, including the keynote lectures from world-renowned leaders in the field, who will present their most recent work and discuss the expected developments in the near future.

Visit website
Immunotherapy Web Featured Images 94

Ide-cel in R/R myeloma: patient-reported outcomes and resistance

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the details of a number of studies investigating idecabtagene vicleucel (ide-cel), a BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy, in relapsed/refractory (R/R) multiple myeloma patients.

Visit website
Immunotherapy Web Featured Images 95

ZUMA-5: high ORR and CR for R/R iNHL with axi-cel

  Feb 03 2021 Tagged NHL, CAR-T, axi-cel, FL

David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, gives an update on the ongoing Phase II ZUMA-5 trial (NCT03105336) of axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR)-T cell therapy, for patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma and marginal zone lymphoma (MZL).

Visit website
Immunotherapy Web Featured Images 96

Ianalumab add-on therapy in CLL patients receiving ibrutinib

  Feb 03 2021 Tagged CLL, mAbs

Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, discusses a Phase Ib trial (NCT03400176) of ianalumab plus ibrutinib in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib therapy. Ianalumab (VAY736) is an anti-BAFF-R monoclonal antibody that causes antibody-dependent cellular cytotoxicity of B-cells.

Visit website
Immunotherapy Web Featured Images 97

DREAMM-2: Effects of belantamab mafodotin on patient reported outcomes in myelom...

  Feb 03 2021 Tagged MM, mAbs, QoL

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, shares patient-reported outcomes from the DREAMM-2 study (NCT03525678) of single-agent belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma.

Visit website
Immunotherapy Web Featured Images 98

What are the next steps for CAR-T in myeloma?

  Feb 03 2021 Tagged MM, CAR-T

Sham Mailankody, MBBS, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the future of CAR-T and cellular therapy for multiple myeloma patients. With no currently approved CAR-T therapy for myeloma, he hopes a major advancement will be FDA approval of a BCMA-targeted CAR-T therapy in the near future.

Visit website
Immunotherapy Web Featured Images 99

Magrolimab plus azacitidine in treatment-naïve AML

  Feb 03 2021 Tagged AML, mAbs

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses a Phase Ib trial (NCT03248479) of magrolimab, a novel anti-CD47 antibody, plus azacitidine in untreated acute myeloid leukemia (AML) patients unfit for intensive chemotherapy.

Visit website
VJhemonic15

First-in-human trial of an anti-BCMA ADC for R/R myeloma

  Feb 03 2021 Tagged MM, ADC, anti-BCMA

Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, discusses the results of a Phase I, first-in-human dose-escalation trial (NCT03489525) of MEDI2228 in patients with relapsed/refractory (R/R) multiple myeloma.

Visit website